tradingkey.logo

Elutia Inc

ELUT

2.010USD

-0.030-1.46%
Market hours ETQuotes delayed by 15 min
82.15MMarket Cap
LossP/E TTM

Elutia Inc

2.010

-0.030-1.46%
More Details of Elutia Inc Company
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
Company Info
Ticker SymbolELUT
Company nameElutia Inc
IPO dateOct 08, 2020
CEODr. C. Randal (Randal) Mills, Ph.D.
Number of employees51
Security typeOrdinary Share
Fiscal year-endOct 08
Address12510 Prosperity Drive
CitySILVER SPRING
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code20904
Phone12402471143
Websitehttps://elutia.com/
Ticker SymbolELUT
IPO dateOct 08, 2020
CEODr. C. Randal (Randal) Mills, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew B. (Matt) Ferguson
Mr. Matthew B. (Matt) Ferguson
Chief Financial Officer
Chief Financial Officer
350.42K
+2.35%
Mr. Kevin L. Rakin
Mr. Kevin L. Rakin
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
90.81K
--
Dr. Michelle LeRoux Williams, Ph.D.
Dr. Michelle LeRoux Williams, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
84.83K
+11.21%
Mr. David Colpman
Mr. David Colpman
Independent Director
Independent Director
3.10K
--
Ms. Brigid A. Makes
Ms. Brigid A. Makes
Independent Director
Independent Director
2.00K
--
Ms. Maybelle Jordan
Ms. Maybelle Jordan
Independent Director
Independent Director
--
--
Mr. W. Matthew (Matt) Zuga
Mr. W. Matthew (Matt) Zuga
Independent Director
Independent Director
--
--
Dr. C. Randal (Randal) Mills, Ph.D.
Dr. C. Randal (Randal) Mills, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew B. (Matt) Ferguson
Mr. Matthew B. (Matt) Ferguson
Chief Financial Officer
Chief Financial Officer
350.42K
+2.35%
Mr. Kevin L. Rakin
Mr. Kevin L. Rakin
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
90.81K
--
Dr. Michelle LeRoux Williams, Ph.D.
Dr. Michelle LeRoux Williams, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
84.83K
+11.21%
Mr. David Colpman
Mr. David Colpman
Independent Director
Independent Director
3.10K
--
Ms. Brigid A. Makes
Ms. Brigid A. Makes
Independent Director
Independent Director
2.00K
--
Ms. Maybelle Jordan
Ms. Maybelle Jordan
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Device protection
3.08M
0.00%
Women's health
2.63M
0.00%
Cardiovascular
326.00K
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Device protection
3.08M
0.00%
Women's health
2.63M
0.00%
Cardiovascular
326.00K
0.00%
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Highcape Partners, L.P.
25.87%
Nantahala Capital Management, LLC
8.65%
SilverArc Capital Management, LLC
7.26%
Alyeska Investment Group, L.P.
7.18%
AIGH Capital Management, LLC.
6.07%
Other
44.97%
Shareholders
Shareholders
Proportion
Highcape Partners, L.P.
25.87%
Nantahala Capital Management, LLC
8.65%
SilverArc Capital Management, LLC
7.26%
Alyeska Investment Group, L.P.
7.18%
AIGH Capital Management, LLC.
6.07%
Other
44.97%
Shareholder Types
Shareholders
Proportion
Private Equity
31.94%
Hedge Fund
23.47%
Investment Advisor
13.06%
Investment Advisor/Hedge Fund
4.19%
Individual Investor
2.32%
Research Firm
0.20%
Pension Fund
0.03%
Other
24.80%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
62
29.11M
79.10%
+5.57M
2025Q1
64
28.98M
78.78%
+5.72M
2024Q4
64
24.46M
68.39%
+2.87M
2024Q3
58
23.42M
72.69%
+5.08M
2024Q2
56
17.79M
87.64%
+1.66M
2024Q1
52
14.42M
71.40%
-3.58M
2023Q4
51
15.14M
76.88%
-1.24M
2023Q3
55
16.32M
83.40%
+5.63M
2023Q2
56
8.93M
75.40%
-915.60K
2023Q1
74
8.59M
72.67%
-1.55M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Highcape Partners, L.P.
9.52M
25.87%
+420.00K
+4.62%
Feb 03, 2025
Nantahala Capital Management, LLC
3.18M
8.65%
+320.00K
+11.17%
Mar 31, 2025
SilverArc Capital Management, LLC
2.67M
7.26%
+887.78K
+49.81%
Mar 31, 2025
Alyeska Investment Group, L.P.
2.64M
7.18%
+2.00M
+310.83%
Mar 31, 2025
AIGH Capital Management, LLC.
2.16M
5.86%
+228.45K
+11.84%
Mar 31, 2025
Worth Venture Partners, LLC
1.22M
3.32%
+78.29K
+6.84%
Mar 31, 2025
Birchview Capital, LP
1.19M
3.23%
-37.75K
-3.08%
Mar 31, 2025
Perkins Capital Management, Inc.
1.14M
3.09%
+276.30K
+32.13%
Mar 31, 2025
Knollwood Investment Advisory, LLC
1.03M
2.81%
+100.00K
+10.70%
Mar 31, 2025
The Vanguard Group, Inc.
988.61K
2.69%
+55.87K
+5.99%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Proportion0.01%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI